BioElectronics Company Updates
Thursday, January 8, 2015
“Try It & Tell Us” 7-Day ActiPatch Sample Program Update
The data now includes responses from 1,500 consumers suffering from chronic pain caused by a number of musculoskeletal conditions.
Visit www.bielcorp.com/clinical-evidence/musculoskeletal-pain to see detail of the survey responses. Visit www.facebook.com/ActiPatch to view what people in the UK and Ireland are saying about the products and to hear and see the joy of a user please visit http://youtu.be/YwG60w2YAzA.
Efficacy rates and pain reduction for those who reported efficacy by specific disease and location were:
- Chronic pain efficacy rate was 76% with a 4.40 VAS (52%) pain reduction
- Osteoarthritis efficacy rate was 76% with a 4.49 VAS (53%) pain reduction
- Rheumatoid arthritis efficacy rate was 81% with a 4.61 VAS (53%) pain reduction
- Fibromyalgia efficacy rate was 77% with a 3.94 VAS point (46%) reduction
- Chronic post-surgery pain efficacy rate was 69% with a 4.60 VAS point (53%) reduction
- Neuropathy pain efficacy rate was 70% with a 4.60 VAS point (54%) reduction
- Chronic back pain efficacy rate was 74% with a 4.30 VAS point (51%) reduction
- Chronic Knee pain efficacy rate was 79% with a 4.49VAS point (54%) reduction
- Chronic shoulder pain efficacy rate was 72% with a 4.49 VAS point (55%) reduction
- Chronic hip pain efficacy rate was 79% with a 4.45 VAS point (53%) reduction
ActiPatch® Purchase Intent Follow Up Survey
Consumers that previously used the 7-Day sample and responded to the survey were surveyed again after a minimal 3 month interval. The survey was limited to consumers who had responded on the 7-Day trial survey and marked an intention to, or maybe purchase the full version of the ActiPatch device from a commercial location. The purpose of this survey was to collect data on the extent of purchasing and clinical benefit of ActiPatch over a 3 month period after the use of the 7-Day Trial sample by chronic pain sufferers in the UK and Ireland.
The first goal was to assess if these people had indeed purchased a commercial ActiPatch, their location of purchase and how many devices had been purchased. The second goal was to determine if continued use of ActiPatch had long term benefit for users and how it had impacted their pain, quality of life and pain medication use.
Results: The responses from the survey which had a 25% response rate were very positive. Over 80% of the consumers who had marked intent to “purchase” or “maybe purchase” had purchased an ActiPatch from a commercial location. The number of intent to, or maybe purchase the ActiPatch device from the 7-Day survey was on average around 75%. Therefore it can be concluded that approximately 60% who trial the 7-Day sample device purchase the full commercial ActiPatch device. The number of devices purchased by these individuals is on average 1.75, which equates to 1.1 units sold per sample.
The data from the survey also indicated that with long term use of ActiPatch, consumers experience on average a large decrease in their pain, a global quality of life improvement and a decreased reliance on pain medications. Taking these three assessment tools together, it can be concluded that ActiPatch is an effective pain therapy for an array of musculoskeletal pain conditions over an extended period.
Sustained improvements in chronic pain, quality of life improvements and reduction of medication use strongly indicates that the consumers will continue to use and purchase the ActiPatch device.
A full write up of the survey will be posted soon.
UK Boots PR & Marketing Update
UK TV Advertising
ActiPatch TV commercials began airing on December 27 and will continue throughout January. The commercials include testimonials from real users along with general information about the product. Our goal is to create awareness about our Try It & Tell Us sample program. The networks that are airing the commercials are FOX, Universal, SyFy, Movies 24, ITV3 and UK TV.
To see the new commercials http://www.youtube.com/user/ActiPatchRelief
ActiPatch Social Media
BioElectronics continues to advertise the 7-Day Sample campaign on Facebook along with interacting with UK and Ireland consumers. We have sent 3,451 samples to the UK and Ireland in December. We continue to receive testimonials from users and post new ones to our website at www.actipatch.com/testimonials.
OTC Pharma Asia Conference 2014
BioElectronics Executive Vice President, Dr. Deepak Kotak has been invited to present BioElectronics’ innovative chronic pain therapy at the OTC Pharma Asia Conference, on Tuesday, March 3, 2015 in Singapore.
Dr. Kotak, an anesthesiologist, talk “ActiPatch® Pain Therapy – Changing the Paradigm of OTC Chronic Pain” describes the science and how this new OTC drug-free therapy is transforming pain management and bringing “life-changing relief” to chronic pain sufferers.
BioElectronics Social Media
Next Company Update: Thursday, February 5, 2015
To receive investor updates via e-mail, please contact us at IR@bielcorp.com with your name and e-mail address. Updates are posted every other Thursday. Thank you for your support!